Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

Ambroxol showed target engagement in Parkinson's dementia but no significant cognitive improvement over placebo. The drug, a common cough medicine in Europe, was safe and well-tolerated.

A COMMON cough medicine could help protect against dementia. A study found that it prevented people with Parkinson’s develop the memory-destroying disease. Around 145,000 people in the UK hav… ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol - a cough medicine used safely for decades in Europe ...

A landmark study by London researchers investigating the use of a cough medicine called Ambroxo to slow the progression of ...

GFAP levels increased in the placebo group, but stayed stable with Ambroxol, suggesting that the cough medicine may have the potential to protect the brain from faster deterioration under ...